Avacta Therapeutics Promotes Francis Wilson to Chief Scientific Officer to Lead pre|CISION Platform Development
核心洞察
Avacta Therapeutics (搜索) has appointed Francis Wilson (搜索) as Chief Scientific Officer, promoting him from Vice President of Chemistry after demonstrating expertise in developing the company's pre|CISION tumor-activated oncology delivery platform.
Wilson has been instrumental in developing novel intellectual property around the pre|CISION mechanism, particularly the sustained release mechanism that forms the backbone of the FAP-Exd (搜索) (AVA6103) program anticipated to begin clinical testing soon.
The leadership change comes as former CSO Michelle Morrow (搜索) departs to pursue other opportunities, with Wilson bringing over 30 years of medicinal chemistry experience from companies including Roche, Summit Therapeutics, and Cellzome (搜索).
Avacta Therapeutics (搜索) has promoted Francis Wilson (搜索) to Chief Scientific Officer, elevating him from his role as Vice President of Chemistry to lead the clinical-stage biopharmaceutical company's pre|CISION tumor-activated oncology delivery platform. The appointment comes as the company prepares for significant preclinical development and intellectual property generation phases.
Leadership Transition and Strategic Vision
Wilson joined Avacta in September 2022 and has demonstrated extensive expertise in developing the company's proprietary pre|CISION platform. His promotion coincides with the departure of former CSO Michelle Morrow (搜索), who is leaving to pursue other opportunities.
"Francis is the ideal person to take us forward, both internally and across our industry, given his deep knowledge of the working of our unique pre|CISION platform," said Christina Coughlin (搜索), CEO of Avacta Therapeutics (搜索). "Francis has demonstrated his keen ability to foster an environment of innovation, and this has been instrumental in developing significant advances in the options for our pre|CISION platform to be used in the clinic."
Key Contributions to Platform Development
Wilson has been instrumental in developing novel intellectual property around the pre|CISION mechanism, notably the sustained release mechanism that forms the backbone of the FAP-Exd (搜索) (AVA6103) program. This program is anticipated to begin clinical testing in the near term, representing a significant milestone for the company's tumor-specific delivery technology.
"Seeing AVA6103 - the molecule we invented - move to the clinic is a huge success for the Company," Wilson commented. "We will learn more about this program in the clinic and apply that as we continue to develop novel intellectual property around our highly successful pre|CISION platform."
Extensive Industry Experience
Wilson brings over three decades of medicinal chemistry experience to his new role. His career includes positions as Research Scientist at Roche Discovery Welwyn (搜索) (1990-2001), Head of Chemistry at Xenova (搜索) (2001-2003), Director of Chemistry at Cellzome (搜索) (2003-2007), and Director of Chemistry at Summit Therapeutics (2007-2022), where he led multiple programs from discovery into clinical development.
He holds a chemistry degree and Doctor of Philosophy degree from Oxford University and is a Chartered Chemist and Fellow of the Royal Society of Chemistry. Wilson has established himself as an industry leader in medicinal chemistry and serves as a valued external speaker for Avacta.
pre|CISION Platform Technology
The pre|CISION platform represents a proprietary payload delivery system based on fibroblast activation protein (搜索) (FAP (搜索)), a tumor-specific protease. The technology is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues.
The platform comprises an anticancer payload conjugated to a proprietary peptide that serves as a highly specific substrate for FAP (搜索), which is upregulated in most solid tumors (搜索) compared with healthy tissues. This tumor-specific protease cleaves pre|CISION peptide drug conjugates and pre|CISION antibody/Affimer drug conjugates in the tumor microenvironment, releasing active payload in the tumor while reducing systemic exposure and toxicity.
Avacta's innovative pipeline consists of pre|CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage this tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates by allowing dosing optimization to deliver improved patient outcomes.